Abstract
Intranasal (IN) administration could be an attractive mode of delivery for drugs targeting the central nervous system, potentially providing a high bioavailability because of avoidance of a hepatic first-pass effect and rapid onset of action. However, controversy remains whether a direct transport route from the nasal cavity into the brain exists. Pharmacokinetic modeling is proposed to identify the existence of direct nose-to-brain transport in a quantitative manner. The selective dopamine-D2 receptor antagonist remoxipride was administered at different dosages, in freely moving rats, by the IN and intravenous (IV) route. Plasma and brain extracellular fluid (ECF) concentration-time profiles were obtained and simultaneously analyzed using nonlinear mixed-effects modeling. Brain ECF/plasma area under the curve ratios were 0.28 and 0.19 after IN and IV administration, respectively. A multicompartment pharmacokinetic model with two absorption compartments (nose-to-systemic and nose-to-brain) was found to best describe the observed pharmacokinetic data. Absorption was described in terms of bioavailability and rate. Total bioavailability after IN administration was 89%, of which 75% was attributed to direct nose-to brain transport. Direct nose-to-brain absorption rate was slow, explaining prolonged brain ECF exposure after IN compared with IV administration. These studies explicitly provide separation and quantitation of systemic and direct nose-to-brain transport after IN administration of remoxipride in the rat. Describing remoxipride pharmacokinetics at the target site (brain ECF) in a semiphysiology-based manner would allow for better prediction of pharmacodynamic effects.
Footnotes
This work was financially supported by Pfizer Global Research and Development, Sandwich, United Kingdom.
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.
doi:10.1124/dmd.111.040782.
-
ABBREVIATIONS:
- CNS
- central nervous system
- AUC
- area under the curve
- BBB
- blood-brain barrier
- CL
- clearance
- CSF
- cerebral spinal fluid
- CV
- coefficient of variation
- ECF
- extracellular fluid
- F
- bioavailability
- IIV
- interindividual variability
- IN
- intranasal
- IV
- intravenous
- k
- elimination rate constant
- ka
- absorption rate constant
- OFV
- objective function value
- PD
- pharmacodynamic
- PK
- pharmacokinetic
- Q
- intercompartmental clearance
- V
- volume of distribution
- VPC
- visual predictive check.
- Received May 19, 2011.
- Accepted September 8, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|